GSK: UBS confirms target price

(CercleFinance.com) - The UK's leading laboratory yesterday morning reported adjusted EPS for Q1 2022 that is up 43% to 32.
8p. UBS highlights strong results from Shingrix and consumer healthcare.

However, following the release, UBS maintained its neutral rating on the stock with a target price of 1,790p.

"GSK reported 1Q'22 turnover of £9,780m, 6.9% above consensus, adjusted operating profit of £2,613m, 10.8% above consensus and adjusted EPS of 32.8p which was 9.3% above consensus of 30.0p," UBS said.

The group also confirmed its FY outlook, still expecting sales growth of 5% to 7% at constant exchange rates in 2022.

It also expects adjusted operating profit to grow by 12% to 14% this year, again at constant exchange rates.

The GSK share is almost exactly flat at 1,796.4 pence this afternoon - pretty much the broker's target price.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.